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Inhibition of PDK-1 activity causes a reduction in cell
proliferation and survival
Peter Flynn*†, Michelle Wong*†, Maryam Zavar*, Nicholas M. Dean‡
and David Stokoe*
3-Phosphoinositide-dependent kinase-1 (PDK-1) was
identified by its ability to phosphorylate and activate
protein kinase B (PKB) in vitro [1,2] and can
phosphorylate and activate additional protein kinases
in the AGC family in vitro [3–6]. Its role in vivo has,
however, only begun to be addressed. We used
antisense oligonucleotides directed against PDK-1
expression to explore the role of PDK-1 in human
glioblastoma cells (U87-MG), which express a mutant
PTEN allele. Reduction in PDK-1 levels resulted in
inhibition of PKB activity, and a reduction in
phosphorylation on Thr308 and Ser473 of PKB. p70 S6
kinase (p70S6K) activity was also reduced. Cell
proliferation was dramatically inhibited following
treatment with PDK-1 antisense oligonucleotides, due
to a combination of decreased cell doubling and an
increase in apoptosis. This is in contrast to direct
inhibition of phosphoinositide 3-OH kinase (PI
3-kinase), which results in G1 arrest with no effect on
apoptosis. This study confirms both PKB and p70S6K as
in vivo substrates for PDK-1. The effect of acute PDK-1
loss on cell proliferation and survival suggests the
involvement of PI 3-kinase dependent and independent
signaling events, and implicates PDK-1 as a potential
therapeutic target for human neoplasms.
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Results and discussion
To evaluate the importance of the role of PDK-1 in PI
3-kinase and PKB signaling in vivo we designed and syn-
thesized a panel of 15 chimeric phosphorothioate anti-
sense oligonucleotides targeted against the nucleotide
sequence of human PDK-1 [7,8]. All 15 oligonucleotides
(ISIS 20466–20480, here termed 66–80) exhibited activity
to various degrees when assayed for their ability to reduce
PDK-1 mRNA levels without affecting β-actin mRNA
levels. The results for oligonucleotides 71–75 are shown in
Figure 1a. We chose two oligonucleotides that were active
in several independent experiments (66 5′-AGCTGG-
CTGGTGGTCCTGGC-3′ and 71 5′-TGAATGATGCC-
CTTGCCGTG-3′, which correspond to nucleotides 4–23
(amino acids 2–8) and 640–659 (amino acids 197–203),
respectively), and synthesized control oligonucleotides
containing 2, 4, 6 and 8 base-pair (bp) mismatches. Intro-
duction of just two mismatches almost completely abol-
ished the ability to inhibit PDK-1 RNA levels (Figure 1b).
Oligonucleotide 71 consistently inhibited PDK-1 RNA
expression by > 90%, so this, together with its 8 bp mis-
match 98, was chosen for further experiments. All experi-
ments were also repeated and confirmed with antisense
oligonucleotide 66 and its 8 bp mismatch 94.
To determine the effects of PDK-1 antisense oligonu-
cleotides on levels of PDK-1 protein and on the activity
of PKB, we used U87-MG cells, a glioblastoma cell line
that expresses a truncated and inactive form of the tumor
suppressor phospholipid phosphatase, PTEN, resulting
in increased PKB activity [9,10]. Over a 96 hour post-
transfection time course, oligonucleotide 71 dramatically
reduced PDK-1 protein levels. Cell numbers increased
(data not shown), hence PKB and PDK-1 protein
(Figure 1) increased during this period in cells treated
with oligonucleotide 98. Reduction in PDK-1 levels
caused a reduction in PKB activity, similar to that caused
by the PI 3-kinase inhibitor LY294002 (Figure 1d). This
suggests that PDK-1 is absolutely required for PKB acti-
vation in U87-MG cells. The polyclonal antisera we used
to immunoprecipitate PKB recognizes all isoforms (α, β
and γ), and the activity of all three was reduced following
treatment with PDK-1 antisense oligonucleotides (data
not shown).
In vitro, PDK-1 catalyzes phosphorylation of PKB exclu-
sively on Thr-308 [1,2,7,8]. In vivo, however, PKB
becomes phosphorylated on both Thr308 and Ser473 fol-
lowing growth factor stimulation [11]. Both phosphoryla-
tion sites are dramatically reduced following treatment of
U87-MG cells with antisense oligonucleotide 71 but not
98 (Figure 2a). This suggests that Ser473 is not phospho-
rylated by a distinctly regulated protein kinase, but does
not distinguish between direct, PDK-1 mediated, phos-
phorylation or PKB autophosphorylation. In addition to
PKB, PDK-1 can also phosphorylate other members of
the AGC protein kinase family, including p70S6K, p90
ribosomal S6 kinase (p90rsk) and protein kinase C related
kinases 1 and 2 (PRKs 1 and 2), at the equivalent phos-
phorylation site in the activation loop [3–6]. p70S6K activ-
ity is inhibited following treatment with PDK-1 antisense
oligonucleotides (Figure 2b). In contrast to p70S6K, p90rsk
and PRKs 1 and 2 were not inhibited by PDK-1 antisense
oligonucleotides (data not shown). These AGC kinase
family members cannot be ruled out as in vivo PDK-1 sub-
strates, however, as kinase inhibition via our short-term
treatment depends on both phosphorylation and dephos-
phorylation of the PDK-1 site. Indeed, for both p90rsk and
the PRKs this site is highly resistant to protein phos-
phatases ([12], and M. Frodin, personal communication).
We next looked at the biological consequences of a
decrease in PDK-1 protein. PDK-1 antisense caused a dra-
matic inhibition of cell proliferation over a 7 day period
following transfection (Figure 3a). The degree of inhibi-
tion was similar to that achieved by LY294002, which
causes arrest of U87-MG cells in the G1 phase of the cell
cycle [13–15]. We therefore investigated whether the
effects of PDK-1 antisense on cell proliferation were also
mediated through this mechanism. PDK-1 antisense had
no effect on the cell-cycle profile of proliferating U87-MG
cells (Figure 3b). They also had only a very modest ability
to prevent G2 arrest induced by nocodazole (Figure 3b),
unlike LY294002 (Figure 3b), and PTEN ([14], and data
not shown). Therefore, a G1 arrest is unlikely to be the
sole reason for the inhibition of cell proliferation. Our
results suggest a pathway emanating from PI 3-kinase that
controls a G1 checkpoint distinct from that involving
PDK-1 and PKB. In support of this, we have been unable
to show G1 arrest following expression of a catalytically
compromised form of PKB which inhibits endogenous
PKB activity, nor have we been able to prevent the G1
arrest induced by LY294002 or PTEN by expressing an
activated form of PKB (data not shown). 
Despite previous experiments implicating PI 3-kinase
and PKB in cell survival signaling, no observable
increases in apoptosis are induced by either LY294002
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Identification of active PDK-1 antisense oligonucleotides. (a) HeLa
cells were transfected with oligonucleotides ISIS 20471–20475
(designated 71–75) or with lipofectin alone (Control), and mRNA
was extracted 24 h later. Northern blots were probed with human
PDK-1 nucleotide sequence, then stripped and reprobed for β-actin.
(b) HeLa cells were transfected with either lipofectin alone or
oligonucleotides ISIS 20471, 30795–30798 (denoted as 71 and
95–98), which contain 0, 2, 4, 6 and 8 bp of mismatch. (c) U87-MG
cells were transfected with either lipofectin alone or oligonucleotides
71 and 98 (300 nM). Cells were lysed at the times indicated (48 h in
the case of the control and LY294002 (LY)-treated cells (20 µM LY
for 20 min)). Equal volumes of lysate were separated by SDS–PAGE
and western blotted using PDK-1- and PKB-specific antibodies.
(d) The lysates from (c) were used to immunoprecipitate PKB which
was then assayed for in vitro kinase activity as described in
Supplementary material.
Figure 2
Inhibition of PDK-1 levels reduces PKB phosphorylation on both Thr308
and Ser473, and inhibits p70S6K activity. U87-MG cells were transfected
with either lipofectin alone (Control), or with PDK-1 oligonucleotides 71
and 98 and harvested 48 h later. LY294002 (20 µM) was added to the
cells 20 min before harvest. (a) PKB activity was assessed as described
for Figure 1. Equal portions of the lysate were separated by SDS–PAGE
and western blotted using antibodies specific for the Thr308 and
Ser473 phosphorylated forms of PKB, and with antibody that recognizes
total PKB. (b) p70S6K was immunoprecipitated from equal amounts of
total protein and assayed for activity as described in the Supplementary
material. A portion of the lysate was separated by SDS–PAGE and
western blotted using antibodies specific for p70S6K.
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or PTEN in attached U87-MG cells [14,16]. Terminal
dUTP nick end labeling (TUNEL) experiments showed,
however, that PDK-1 antisense oligonucleotides caused
substantial apoptosis 48 and 72 hours after oligo-
nucleotide administration, effects similar in magnitude to
those of tumor necrosis factor (TNF) in the presence of
cycloheximide, although somewhat delayed (Figure 4a,b).
The difference between PI 3-kinase inhibition and
PDK-1 antisense treatment in their relative abilities to
cause apoptosis suggests at least two possibilities. The
first is that PDK-1 has substrates in addition to PKB or
p70S6K that could mediate a survival signal independent
of PI 3-kinase signaling. The second possibility is that
PKB (or another protein in the PI 3-kinase pathway) is
the relevant survival substrate, but that inhibition of PI
3-kinase provides additional signals that prevent apopto-
sis. One possibility in this regard is that cells arrested
in G1 are protected from apoptosis. This situation has been
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PDK-1 antisense oligonucleotides abolish cell proliferation but
cause little G1 arrest. (a) Subconfluent U87-MG cells were
transfected in 15 cm dishes with the indicated oligonucleotides, or
treated with 20 µM LY294002. At the indicated times after
transfection cells were trypsinized and viable cells counted by trypan
blue exclusion. (b) U87-MG cells were transfected with the indicated
oligonucleotides or lipofectin alone, or treated with 20 µM
LY294002, and harvested for FACS analysis 72 h later. Where
indicated, nocodazole (70 ng/ml) was added as described in
Supplementary material.
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Loss of PDK-1 activity results in apoptosis. (a) TUNEL staining of
U87-MG cells 48 h after transfection with PDK-1 antisense and
mismatch oligonucleotides, or treatment with 10 ng/ml TNF and
10 µg/ml cycloheximide. Hoechst DNA staining is shown in the top
panels to indicate total cells present, and cells positive for
incorporation of rhodamine dUTP are stained red in the bottom panels.
(b) Quantitation of the percentage of cells staining positive for the
TUNEL assay. Four fields of approximately 400 cells were picked at
random and the number of rhodamine-staining cells over the number of
total cells is indicated. Filled squares, control; filled diamonds,
oligonucleotide 98; filled triangles, oligonucleotide 71; filled circles,
LY294002; stars, TNF + cycloheximide.
described in primary keratinocytes, where induction of
growth arrest in G1 protected cells from apoptosis in-
duced by ultraviolet radiation [17].
We used time-lapse videomicroscopy to analyze the effects
of PDK-1 antisense oligonucleotides on U87-MG prolifera-
tion and survival over 48 hours, beginning 24 hours post-
transfection. The PDK-1-antisense-treated cells were
morphologically distinct from controls, with enlarged, flat-
tened cell bodies and reduced motility. Increased apopto-
sis was also seen towards the end of the time period,
confirming the TUNEL experiments (Figure 4). Surpris-
ingly, and in contrast to the FACS results, there was also a
dramatic effect on the cell cycle, as seen by a decrease in
the number of mitoses in cells treated with PDK-1 anti-
sense relative to controls when normalized for cell number
(see Supplementary material). 
While this paper was in preparation, Williams et al. [18]
published an analysis of embryonic stem (ES) cells in
which a lack of PDK-1 protein expression had been gen-
erated by homologous recombination. They showed that
PKB activity was abolished, in agreement with our study.
However, in contrast to our results , which  show simulta-
neous inhibition of Thr308 and Ser473 phosphorylation,
they showed that although Thr308 phosphorylation
was bolished, Ser473 phosphorylation was almost unaf-
fected. The reason for this discrepancy is unclear, and
shows that the mechanism and role of PKB Ser473 phos-
phorylation in different cell types under different condi-
tions remains to be clarified. The PDK-1–/– ES cells were
also defective in their ability to cause p70S6K activation in
response to IGF-1; this is consistent with our data
showing inhibition of p70S6K by PDK-1 antisense
oligonucleotides. Also, whereas loss of PDK-1 expression
in U87-MG cell causes a dramatic decrease in cell prolif-
eration, the PDK-1–/– ES cells were viable and grew nor-
mally. All these discrepancies suggest that the role of
PDK-1 may be distinct in different cell types and that
the acute removal of PDK-1 protein is not functionally
the same as genetic deletion.
The effect of PDK-1 antisense oligonucleotides on prolif-
eration and apoptosis in U87-MG cells suggests that
PDK-1 inhibition might be a useful therapeutic strategy
under conditions of chronic PI 3-kinase signaling. Investi-
gation into which PDK-1 substrates mediate these effects
is currently underway. 
Supplementary material
Supplementary material including detailed methodologies, a figure showing
mitotic index and movies of U87-MG cell proliferation after antisense treat-
ments is available at http://current-biology.com/supmat/supmatin.htm.
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